SuperGen Inc, a US development-stage drug company, has received orphan drug status from the US Food and Drug Administration for its antiobesity pill RF1051, in the treatment of Prader-Willi syndrome.
The drug is currently in Phase I/II human trials for PWS, a rare chronic genetic disease characterized by extreme obesity, short stature and mental retardation, which affects an estimated 15,000 persons in the USA. The product is also in Phase II for the treatment of general obesity.
Previously, SuperGen had been given orphan drug status - as well as an orphan drug grant for development expenses from the FDA - for its drug RF1017 for the treatment of aplastic anemia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze